Enaksha Wickremsinhe

Case Studies on the Use of Patient-centric Sampling for Clinical Studies in Pharmaceutical Drug Development

Shefali Patel, Mike Baratta, Peter Bryan, Hagit Kopel et autres

us, il, gb, be, es (code pays fourni par la source)

Best Practices and Recommendations for Non-Liquid Matrices Bioanalysis

Faye Vazvaei‐Smith, Wenkui Li, Omar S. Barnaby, Sanjeev Bhardwaj et autres

us, ch, ca (code pays fourni par la source)

ICH M10 Bioanalytical Method Validation Guideline-1 year Later

Faye Vazvaei‐Smith, Enaksha Wickremsinhe, Eric Woolf, Chongwoo Yu

us (code pays fourni par la source)

Perspectives on Adopting Patient Centric Sampling for Pediatric Trials

Enaksha Wickremsinhe

us (code pays fourni par la source)

Microsampling in Pediatric Studies: Pharmacokinetic Sampling For Baricitinib (Olumiant™) in Global Pediatric Studies

Enaksha Wickremsinhe, Rodney L. Decker, Lisa B Lee, Erica Lelle et autres

us (code pays fourni par la source)

Supplementary Figure 2 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho et autres

Supplementary Figure Legend from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho et autres

Supplementary Figure 1 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho et autres

Supplementary Figure 1 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho et autres

Supplementary Figure Legend from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho et autres

Supplementary Figure 2 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho et autres

Data from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

Susan E. Pratt, Sara Durland–Busbice, Robert L. Shepard, Gregory P. Donoho et autres